Cargando…
Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases
OBJECTIVE: Evaluation of the implementation of pharmaceutical services to detect comorbidities in at-risk patients. METHODS: This study was carried out in community pharmacies across Poland in 2019 inside the specially designed service “Refer the Patient”. The project was intended for patients with...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294810/ https://www.ncbi.nlm.nih.gov/pubmed/34305397 http://dx.doi.org/10.2147/PPA.S312341 |
_version_ | 1783725307131330560 |
---|---|
author | Lewicki, Jędrzej Religioni, Urszula Merks, Piotr |
author_facet | Lewicki, Jędrzej Religioni, Urszula Merks, Piotr |
author_sort | Lewicki, Jędrzej |
collection | PubMed |
description | OBJECTIVE: Evaluation of the implementation of pharmaceutical services to detect comorbidities in at-risk patients. METHODS: This study was carried out in community pharmacies across Poland in 2019 inside the specially designed service “Refer the Patient”. The project was intended for patients with selected chronic diseases. The patients were identified on the basis of their medications (active substances). At-risk patients were referred for prophylactic examinations to detect comorbidities. RESULTS: A total of 78 pharmacies took part in this study and 209 at-risk patients were identified. Out of the patients referred for examinations, 30% had deviant results, and 0.95% were diagnosed with new diseases. CONCLUSION: Pharmaceutical services supporting screening tests among at-risk patients are highly recommended. Pharmacist intervention allows for early detection of comorbidities and prompt treatment. The pharmaceutical service “Refer the Patient” makes it possible to detect a disease at an early stage. Rapid implementation of treatment can prevent serious health consequences, maintains patient quality of life, and reduce treatment costs. |
format | Online Article Text |
id | pubmed-8294810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82948102021-07-22 Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases Lewicki, Jędrzej Religioni, Urszula Merks, Piotr Patient Prefer Adherence Original Research OBJECTIVE: Evaluation of the implementation of pharmaceutical services to detect comorbidities in at-risk patients. METHODS: This study was carried out in community pharmacies across Poland in 2019 inside the specially designed service “Refer the Patient”. The project was intended for patients with selected chronic diseases. The patients were identified on the basis of their medications (active substances). At-risk patients were referred for prophylactic examinations to detect comorbidities. RESULTS: A total of 78 pharmacies took part in this study and 209 at-risk patients were identified. Out of the patients referred for examinations, 30% had deviant results, and 0.95% were diagnosed with new diseases. CONCLUSION: Pharmaceutical services supporting screening tests among at-risk patients are highly recommended. Pharmacist intervention allows for early detection of comorbidities and prompt treatment. The pharmaceutical service “Refer the Patient” makes it possible to detect a disease at an early stage. Rapid implementation of treatment can prevent serious health consequences, maintains patient quality of life, and reduce treatment costs. Dove 2021-07-17 /pmc/articles/PMC8294810/ /pubmed/34305397 http://dx.doi.org/10.2147/PPA.S312341 Text en © 2021 Lewicki et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lewicki, Jędrzej Religioni, Urszula Merks, Piotr Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title | Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title_full | Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title_fullStr | Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title_full_unstemmed | Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title_short | Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases |
title_sort | evaluation of the community pharmacy comorbidities screening service on patients with chronic diseases |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294810/ https://www.ncbi.nlm.nih.gov/pubmed/34305397 http://dx.doi.org/10.2147/PPA.S312341 |
work_keys_str_mv | AT lewickijedrzej evaluationofthecommunitypharmacycomorbiditiesscreeningserviceonpatientswithchronicdiseases AT religioniurszula evaluationofthecommunitypharmacycomorbiditiesscreeningserviceonpatientswithchronicdiseases AT merkspiotr evaluationofthecommunitypharmacycomorbiditiesscreeningserviceonpatientswithchronicdiseases |